ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF ADVATE IN PROPHYLACTIC TREATMENT OF HEMOPHILIA A PATIENTS


Abstract


The objective of this project has been to develop an HTA on Advate, octocog alfa, third-generation ricombinant factor VIII for the treatment and prophylaxis of bleeding episodes in patients affected by Hemophilia A in order to analyse the product’s potentials and limitations in the context of the epidemiological, clinical, economic and organisational situation in Italy.


Full Text:

PDF


DOI: https://doi.org/10.2427/8715

NBN: http://nbn.depositolegale.it/urn%3Anbn%3Ait%3Aprex-9289

References



Refbacks

  • There are currently no refbacks.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it (Read more).
Ok